Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18 EUR | -8.07% | -1.16% | +75.29% |
May. 15 | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
May. 09 | Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.29% | 1.76B | |
+11.12% | 115B | |
+12.58% | 106B | |
-4.09% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.11% | 17.56B | |
-40.50% | 17.32B | |
+6.54% | 14.03B | |
+31.89% | 12.13B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M